Compared to  unfractionated heparin  what was the result of fondaparinux 2.5 mg once daily on death or recurrent myocardial infarction in patients undergoing primary percutaneous coronary interventions?
 At day 30, fondaparinux significantly reduced the occurrence of the primary efficacy outcome (death or recurrent myocardial infarction) by 14% (p=0.008